P
Paul Lochhead
Researcher at Harvard University
Publications - 105
Citations - 8641
Paul Lochhead is an academic researcher from Harvard University. The author has contributed to research in topics: Colorectal cancer & Prospective cohort study. The author has an hindex of 35, co-authored 95 publications receiving 6874 citations. Previous affiliations of Paul Lochhead include Aberdeen Royal Infirmary & University of Aberdeen.
Papers
More filters
Journal ArticleDOI
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
Aleksandar Kostic,Aleksandar Kostic,Eunyoung Chun,Lauren Robertson,Jonathan N. Glickman,Carey Ann Gallini,Monia Michaud,Thomas E. Clancy,Thomas E. Clancy,Daniel C. Chung,Paul Lochhead,Georgina L. Hold,Emad M. El-Omar,Dean E. Brenner,Charles S. Fuchs,Matthew Meyerson,Matthew Meyerson,Wendy S. Garrett +17 more
TL;DR: Data suggest that, through recruitment of tumor-infiltrating immune cells, fusobacteria generate a proinflammatory microenvironment that is conducive for colorectal neoplasia progression, and this work finds that F.nucleatum does not exacerbate colitis, enteritis, or inflammation-associated intestinal carcinogenesis.
Journal ArticleDOI
Long-Term Colorectal-Cancer Incidence and Mortality after Lower Endoscopy
Reiko Nishihara,Kana Wu,Paul Lochhead,Teppei Morikawa,Xiaoyun Liao,Zhi Rong Qian,Kentaro Inamura,Sun A. Kim,Aya Kuchiba,Mai Yamauchi,Yu Imamura,Walter C. Willett,Bernard Rosner,Charles S. Fuchs,Edward Giovannucci,Shuji Ogino,Andrew T. Chan +16 more
TL;DR: Colorectal cancer diagnosed within 5 years after colonoscopy was more likely than cancer diagnosed after that period or without prior endoscopy to have CIMP and microsatellite instability and colonoscopic was also associated with a modest reduction in the incidence of proximal colon cancer.
Journal ArticleDOI
Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.
Xiaoyun Liao,Paul Lochhead,Reiko Nishihara,Teppei Morikawa,Aya Kuchiba,Mai Yamauchi,Yu Imamura,Zhi Rong Qian,Yoshifumi Baba,Kaori Shima,Ruifang Sun,Katsuhiko Nosho,Jeffrey A. Meyerhardt,Edward Giovannucci,Charles S. Fuchs,Andrew T. Chan,Shuji Ogino +16 more
TL;DR: The findings from this molecular pathological epidemiology study suggest that the PIK3CA mutation in colorectal cancer may serve as a predictive molecular biomarker for adjuvant aspirin therapy.
Journal ArticleDOI
Microsatellite Instability and BRAF Mutation Testing in Colorectal Cancer Prognostication
Paul Lochhead,Aya Kuchiba,Yu Imamura,Xiaoyun Liao,Mai Yamauchi,Reiko Nishihara,Zhi Rong Qian,Teppei Morikawa,Jeanne Shen,Jeffrey A. Meyerhardt,Charles S. Fuchs,Shuji Ogino +11 more
TL;DR: Combined BRAF/MSI status in colorectal cancer is a tumor molecular biomarker for prognosic risk stratification and no evidence existed for a differential prognostic role of BRAF mutation by MSI status.
Journal ArticleDOI
Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review
Xiaoyun Liao,Teppei Morikawa,Paul Lochhead,Yu Imamura,Aya Kuchiba,Mai Yamauchi,Katsuhiko Nosho,Zhi Rong Qian,Reiko Nishihara,Jeffrey A. Meyerhardt,Charles S. Fuchs,Shuji Ogino +11 more
TL;DR: Coexistence of PIK3CA (the PI3K p110α subunit) exon 9 and 20 mutations, but not Pik3CA mutation in either exon 7 or 20 alone, is associated with poor prognosis of colorectal cancer patients.